Connect with us

International

CBG (Cannabigerol) reduces anxiety and stress, reveals clinical trial

Published

em

Listen to this article
Photo: DR | Herbiesheadshop.com

Results from a new clinical trial show that CBG (Cannabigerol) was effective in reducing anxiety and stress, as well as improving verbal memory, compared to a placebo. In a randomized, double-blind, placebo-controlled clinical trial by Ethan Russo, Carrie Cuttler, Amanda Stueber, and Ziva D. Cooper, the acute effects of CBG on anxiety, stress, and mood were examined. “This study is important because it is the first human clinical trial of CBG for a symptom, anxiety, and that it has reached statistical significance without evidence of impairment,” says Ethan Russo.

Speaking to CannaReporter®, the neurologist and psychopharmacologist responsible for the study, Ethan Russo, explained that this was “a randomized and controlled clinical trial, carried out via Zoom, with people taking 20 mg of cannabigerol (CBG) or placebo in their environment domestic while interacting with a researcher and performing online cognition/memory tasks and assessing anxiety and stress levels.”

CBG turned out to be a promising compound: “it had an anxiolytic effect at a dose of 5% of that required for pure cannabidiol (CBD). The fact that this effect was observed, without evidence of sedation, and with an actual statistically significant improvement in memory, is quite remarkable. CBG is proving to be a very useful addition to our formulation work due to its safety and versatility in treating many chronic symptoms,” said Ethan Russo, who led the study.

Furthermore, the team also investigated whether CBG produced side effects or motor and cognitive impairments, as is the case with other cannabinoids such as THC.


Clinical trial methodology

For the study, 34 healthy participants were recruited and administered a CBG tincture consisting of 20 mg/ml CBG, 0,89 mg/ml CBGA, 0,35 mg/ml β-caryophyllene (0. 51 mg/ml total terpenoids) with less than 0,001 mg.

Each participant completed two testing sessions, interspersed with a one-week break period, during which they assessed anxiety, stress, mood and the subjective effects of the oil before administration, in a series of standardized questionnaires.

After analyzing the results, researchers found that CBG oil had a “significant main effect” on subjective ratings of anxiety, representing a 26,5% reduction in anxiety levels, as well as a “significant effect” on subjective ratings. of stress.

Although the study did not demonstrate anti-depressant effects, according to the authors, CBG significantly improved verbal memory.

“We hypothesized that CBG would not impair memory, but we found that CBG significantly improved verbal memory, which was unexpected,” they say.

CBG does not reveal cognitive or motor impairments
According to the scores recorded by the Driving under the influence of drugs (DRUID) application, CBG did not cause cognitive or motor impairments and participants did not report intoxication effects.

“The results of this randomized, double-blind, placebo-controlled trial indicate that 20 mg of hemp-derived CBG reduces subjective ratings of anxiety and stress in healthy adults using cannabis, by the absence of motor or cognitive impairment, intoxication or other subjective effects of the substance”, state the authors.

Thus, “CBG may represent a new option for reducing stress and anxiety in healthy adults,” the researchers conclude.

Cuttler_et_al Acute effects of cannabigerol on anxiety, stress and mood A double-blind, placebo-controlled, crossover, field trial Scientific Reports 2024

 

____________________________________________________________________________________________________

[Disclaimer: Please note that this text was originally written in Portuguese and is translated into English and other languages ​​using an automatic translator. Some words may differ from the original and typos or errors may occur in other languages.]

____________________________________________________________________________________________________

What do you do with €3 a month? Become one of our Patrons! If you believe that independent cannabis journalism is necessary, subscribe to one of the levels of our Patreon account and you will have access to unique gifts and exclusive content. If there are many of us, we can make a difference with little!

+ posts

With a degree in Journalism from the University of Coimbra, Laura Ramos has a postgraduate degree in Photography and has been a Journalist since 1998. She was a correspondent for Jornal de Notícias in Rome, Italy, and Press Advisor at the Office of the Minister of Education. She has an international certification in Permaculture (PDC) and created the street-art photographic archive “What says Lisbon?” @saywhatlisbon. Laura is currently Editor of CannaReporter and CannaZine, as well as founder and program director of PTMC - Portugal Medical Cannabis. She directed the documentary “Pacientes” and was part of the steering group of the first Postgraduate in GxP's for Medicinal Cannabis in Portugal, in partnership with the Military Laboratory and the Faculty of Pharmacy of the University of Lisbon.

Click here to comment
Subscribe
Notify of

0 Comments
Inline feedback
View all comments
Advertising


Watch the Documentary "Patients"

Documentary Patients Laura Ramos help us grow

Mais recentes

International1 hours ago

Pakistan wants a regulated cannabis industry, but with a 0,3% THC limit

Pakistan is set to establish its own medicinal cannabis industry, with the National Assembly set to vote...

International5 days ago

Volkswagen invests in industrial hemp leather for car interiors

After brands such as Ford, BMW or Mercedes, Volkswagen has started a cooperation with the German start-up Revoltech GmbH...

International5 days ago

Jazz Pharmaceuticals fails Phase 3 Epidyolex clinical trial in Japan

Pharmaceutical giant Jazz recently announced that its leading cannabinoid treatment, Epidyolex, failed clinical trials...

Press Releases6 days ago

UK: Landlords risk breaching Equality Act over prescribed cannabis

Landlords, property managers and housing associations are currently at risk of breaching the Equality Act due to...

International6 days ago

USA: New York destroys four tons of cannabis products worth $63 million

City officials in New York City have incinerated more than four tons of unregulated cannabis products...

Events7 days ago

Product Earth kicks off in London next weekend

The 9th edition of Product Earth will take place on the 7th and 8th of September, at Drumsheds, in London, United Kingdom...

International7 days ago

USA – Legalization did not increase cannabis use, but reduced alcohol consumption and surpassed it

Young Americans are using less cannabis today than in 2014, but for the first time since...

Press Releases1 weeks ago

VertiFarm will showcase the latest technological trends and innovations for cannabis production

International trade fair to provide information on efficient cultivation options for useful, nutritious and health-promoting cannabis products and applications...

Press Releases2 weeks ago

Cannabis Industry Council, Medical Cannabis Clinicians Society and Drug Science Announce Cannabis Industry Awards

The inaugural Cannabis Industry Awards Dinner was announced by the Cannabis Industry Council, Medical Cannabis...

Press Releases2 weeks ago

Cosma SA and SOMAÍ Pharmaceuticals partner to revolutionize Poland with the most innovative cannabis-based solutions

Cosma SA, a leader in cannabis-based pharmaceutical advancements, and SOMAÍ Pharmaceuticals, a fully integrated Multinational Operator (MCO)...